HealthQuartzabout 1 hour ago
Merck buys UK biotech Silence for $1.3 billion
1 min read
Germany's Merck KGaA agreed to acquire U.K. gene-silencing biotech Silence Therapeutics for about $1.3 billion in cash. The deal adds divesiran, an experimental rare-disease drug ready for late-stage trials, to Merck KGaA's pipeline. Silence stock rose 4% on Monday before the market opened.
Level
Hype check
Tap to vote and see what everyone thinks.